# Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

> **NCT04678505** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 9 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** MK-3402

## Key facts

- **NCT ID:** NCT04678505
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-10
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-04-27
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678505, "Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04678505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*